Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Vigo – page 10

308 clinical trials in Vigo, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Vigo at a glance
308
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

308 trials in Vigo

Open in trial search

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Dermatitis atopic+1

Not yet recruiting

Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Malignant peritoneal neoplasm+2

Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Cardiac failure chronic+1

Not yet recruiting

Effect of oral urea on hyponatremia and fluid overload in adults with acute and chronic heart failure

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Urea
  • Sponsor:Nutricion Medica S.L.

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Phase 2b Randomized Double‑Blind Study of ALN‑CIDEB in Adults with Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Vigo

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer treatments, including studies for gastric cancer, non-small cell lung cancer, and breast cancer. Research involves combination therapies and novel treatment approaches.

  • Advanced gastric and gastroesophageal cancer treatments
  • Targeted therapies for lung cancer
  • Triple-negative breast cancer interventions

Multiple studies evaluating immunotherapy combinations and chemotherapy protocols for improved patient outcomes.

02 Infectious Diseases

Comprehensive research programs examining treatments for HIV infections and influenza, including preventive measures and therapeutic interventions.

  • HIV pre-exposure prophylaxis studies
  • Influenza vaccine efficacy trials
  • Antiviral therapy evaluations

Focus on developing improved prevention strategies and treatment options for viral infections.

03 Cardiovascular Research

Studies investigating treatments for heart failure prevention and atrial fibrillation, with emphasis on innovative therapeutic approaches.

  • Heart failure risk reduction studies
  • Anticoagulation therapy research
  • Cardiovascular disease prevention

Evaluating new drug combinations and treatment strategies for improved cardiac outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.